BridgeBio Pharma Inc
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +2.54%.
Did BBIO Beat Earnings? Q2 2025 Results
BridgeBio Pharma delivered a split verdict in Q2 2025, posting revenue of $110.56 million that exceeded the $88.78 million consensus by 24.54% while reporting a loss per share of $0.95, wider than the $0.60 consensus estimate by 57.02%. The revenue figure represents a staggering 4,999.9% increase year-over-year, reflecting the company's rapid transformation from clinical-stage to commercial-stage biotech on the back of Attruby, its ATTR-CM therapy, which generated $71.50 million in U.S. net product revenue, nearly doubling from the prior quarter. The deeper loss, with net losses widening to $181.90 million from $73.46 million a year ago, stems directly from a $69.60 million surge in SG&A expenses tied to the Attruby commercial launch. Analysts have since raised both their revenue and loss estimates for 2025, reflecting the inherent costs of scaling a new commercial operation. Looking ahead, BridgeBio expects Phase 3 topline readouts for BBP-418 and encaleret in fall 2025, catalysts that could meaningfully redefine the company's long-term profile, with management characterizing its $756.89 million cash position as sufficient to fund both the launch and pipeline milestones.
- Accelerating Attruby commercial launch with product revenue nearly doubling quarter-over-quarter
- Growing adoption across centers of excellence and community physicians with 3,751 unique patient prescriptions by 1,074 unique prescribers
- Strong month-over-month growth in treatment-naïve patient segment
- $30 million regulatory milestone from Alexion upon Japan pricing approval of BEYONTTRA
- New ATTRibute-CM analyses reinforcing Attruby's differentiated clinical profile including 59% relative risk reduction in variant ATTR-CM patients
“The launch of Attruby continues to accelerate, increasing the number of patients' lives we are able to touch. We remain grateful for the physicians and patients who are partnering with us on both treatment and on new clinical research.”
BridgeBio Pharma CEO, on the earnings call
Forward Guidance & Outlook
BridgeBio expects a transformative next six months with multiple Phase 3 readouts: topline results from FORTIFY (BBP-418 for LGMD2I/R9) and CALIBRATE (encaleret for ADH1) are expected in fall 2025, while PROPEL 3 (infigratinib for achondroplasia) topline results are expected in early 2026. The company plans to file for Accelerated Approval in the U.S. for BBP-418 if the interim analysis supports it. Clinical development of infigratinib for children under 3 years old with achondroplasia is expected to initiate by year-end. A late-stage clinical study for encaleret in chronic hypoparathyroidism is planned for 2026. The company expects enrollment completion for the Phase 2 portion of ACCEL 2/3 in hypochondroplasia in H2 2025. Additional Attruby data will be presented at ESC Congress in August 2025. BridgeBio ended Q2 with $756.9 million in cash and marketable securities, which management characterizes as well capitalized to continue the Attruby launch and deliver Phase 3 results.
BBIO YoY Financials
BBIO Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.